ADAM17 and COVID-19: The field searching for therapy for COVID-19 is wide, with several open questions; as ADAM17 mediates activation of a vast number of proteins, we propose that solTNFR1 be considered a target in the development of new therapeutic immunomodulation for SARS-CoV2 infection.